Patents by Inventor Lianshan Zhang

Lianshan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10562977
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: February 18, 2020
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali Wang, Lianshan Zhang, Jindong Liang, Ang Li, Fanglong Yang
  • Publication number: 20200040078
    Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.
    Type: Application
    Filed: October 9, 2017
    Publication date: February 6, 2020
    Inventors: Xing SUN, Guoqing CAO, Changyong YANG, Lianshan ZHANG, Yong GUO
  • Publication number: 20200030453
    Abstract: A method for preparing an antibody-drug conjugate (ADC). In particular, the method mainly utilizes a combination of antibody biomolecules and an ion exchange carrier through electrostatic interaction to realize solid phase preparation of an ADC drug. Elution conditions are optimized, to control a drug-to-antibody coupling ratio (DAR) and separate a polymer-coupled drug, reduce the amount of a drug used in a coupling reaction, and enhance the targeted therapeutic effect of an ADC drug. The preparation method features fewer steps, simple operation, and programmable control, facilitating industrial scale-up production, and also realizing zero retention of reducing agents and organic solvents in the preparation process, significantly improving drug safety and reducing production costs.
    Type: Application
    Filed: March 29, 2018
    Publication date: January 30, 2020
    Inventors: Yupeng Liu, Xiaofei Zhang, Zhi Liang, Ruijun Shi, Jin Zhong, Xun Liu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Publication number: 20200031934
    Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.
    Type: Application
    Filed: March 30, 2018
    Publication date: January 30, 2020
    Inventors: Jinming GU, Xiaohua WANG, Xin YE, Liuqing YANG, Ting ZHANG, Weikang TAO, Lianshan ZHANG
  • Patent number: 10543284
    Abstract: Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: January 28, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jiajian Liu, Lianshan Zhang, Weikang Tao, Yayuan Fu, Ling Zhang, Dong Ma, Dongbing Cui, Yali Wang, Jianyan Xu, Jindong Liang, Ying Zhang, Guiyang Jiang, Junzhuan Qiu, Ziyong Sun, Jiping Zha, Jingping Wei
  • Patent number: 10449250
    Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: October 22, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jiajian Liu, Yayuan Fu, Haoying Zhang, Yifang Wang, Zhen Zhang, Ling Zhang, Dongbing Cui, Lianshan Zhang, Weikang Tao
  • Publication number: 20190315886
    Abstract: Provided are a thrombin antibody, an antigen-binding fragment and a pharmaceutical use thereof. Further provided are a chimeric antibody and a humanized antibody comprising a thrombin antibody CDR region, and a pharmaceutical composition comprising the thrombin antibody and the antigen-binding fragment thereof, as well as the use thereof as an anticoagulant drug. In particular, provided is a use of the humanized thrombin antibody in preparing a drug for treating a thrombin-mediated disease or condition.
    Type: Application
    Filed: February 3, 2017
    Publication date: October 17, 2019
    Inventors: Hua YING, Jiajian LIU, Yayuan FU, Ling ZHANG, Haoying ZHANG, Jiakang SUN, Lianshan ZHANG, Weikang TAO, Piaoyang SUN, Qiyue HU
  • Publication number: 20190309069
    Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.
    Type: Application
    Filed: May 30, 2019
    Publication date: October 10, 2019
    Inventors: Jijun YUAN, Xiangdong QU, Jufang LIN, Xin YE, Guoqing CAO, Weikang TAO, Lianshan ZHANG, Lei ZHANG, Li YANG
  • Publication number: 20190275021
    Abstract: A combination of a VEGFR inhibitor and a PARP inhibitor is described. In particular, this combination can be used in the preparation of a medicament for treating gastric cancer.
    Type: Application
    Filed: November 30, 2017
    Publication date: September 12, 2019
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Jiahua JIANG, Guoqing CAO, Changyong YANG, Lianshan ZHANG, Jianjun ZOU, Piaoyang SUN
  • Publication number: 20190233513
    Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.
    Type: Application
    Filed: June 22, 2017
    Publication date: August 1, 2019
    Inventors: Zhuoxiao Cao, Yayuan Fu, Qiyue Hu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Publication number: 20190225698
    Abstract: An anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use of the same are described. Further, provided are a chimeric antibody comprising a CDR of the anti-CD27 antibody, a humanized antibody, a pharmaceutical composition comprising a human anti-CD27 antibody or an antigen-binding fragment thereof, and use of the same as an anti-cancer drug. The present invention particularly relates to a human anti-CD27 antibody and use thereof in preparing a drug for treating a CD27-mediated disease or disorder.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 25, 2019
    Inventors: Shude YAN, Jiahua JIANG, Lianshan ZHANG, Guoqing CAO
  • Patent number: 10344090
    Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: July 9, 2019
    Assignees: Shanghai Hangrui Pharmaceutical Co., Ltd., Jiangsu Hangrui Medicine Co., Ltd.
    Inventors: Jijun Yuan, Xiangdong Qu, Jufang Lin, Xin Ye, Guoqing Cao, Weikang Tao, Lianshan Zhang, Lei Zhang, Li Yang
  • Publication number: 20190070264
    Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.
    Type: Application
    Filed: November 17, 2015
    Publication date: March 7, 2019
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong QU, Xin YE, Qiyue HU, Dongbing CUI, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • Patent number: 10206980
    Abstract: Provided is an IL-15 heterodimeric protein, such as an IL-15/IL-15R? heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15R? or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a “Knob-into-Hole” mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: February 19, 2019
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong Qu, Xin Ye, Jijun Yuan, Lei Zhang, Kan Chen, Lianshan Zhang, Guoqing Cao, Zhibin Xu, Weikang Tao
  • Publication number: 20190016825
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.
    Type: Application
    Filed: December 20, 2016
    Publication date: January 17, 2019
    Inventors: Xiangdong QU, Xin YE, Shaoyu XU, Bei YUAN, Dongbing CUI, Qiyue HU, Lei ZHANG, Zhibin XU, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • Publication number: 20180339045
    Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.
    Type: Application
    Filed: September 14, 2016
    Publication date: November 29, 2018
    Inventors: Jie LI, Zhen YAN, Pingping WANG, Yan FANG, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • Publication number: 20180334504
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 22, 2018
    Applicants: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong QU, Qiyue HU, Shaoyu XU, Dongbing CUI, Houcong JIN, Weikang TAO, Lianshan ZHANG, Guoqing CAO, Piaoyang SUN
  • Publication number: 20180177890
    Abstract: Provide are ligand-cytotoxic drug conjugates with a general formula of PC-L-Dr, a preparation method thereof, and uses of the ligand-cytotoxic drug conjugate and pharmaceutical compositions containing the same in preparing drugs for treating cancers by means of receptor regulation.
    Type: Application
    Filed: January 26, 2016
    Publication date: June 28, 2018
    Inventors: Jianyan XU, Ying ZHANG, Bolei QU, Fuyao ZHANG, Xiuzhao YU, Jindong LIANG, Guiyang JIANG, Lianshan ZHANG, Ang LI, Yali WANG
  • Publication number: 20180110875
    Abstract: Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.
    Type: Application
    Filed: April 7, 2016
    Publication date: April 26, 2018
    Inventors: Jiajian LIU, Lianshan ZHANG, Weikang TAO, Yayuan FU, Ling ZHANG, Dong MA, Dongbing CUI, Yali WANG, Jianyan XU, Jindong LIANG, Ying ZHANG, Guiyang JIANG, Junzhuan QIU, Ziyong SUN, Jiping ZHA, Jingping WEI
  • Publication number: 20180099046
    Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).
    Type: Application
    Filed: February 16, 2016
    Publication date: April 12, 2018
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jiajian LIU, Yayuan FU, Haoying ZHANG, Yifang WANG, Zhen ZHANG, Ling ZHANG, Dongbing CUI, Lianshan ZHANG, Weikang TAO